Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH)3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.
Manservigi
Roberto
R
Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Via Luigi Borsari 46, 44100 Ferrara, Italy. mns@unife.it
Boero
Anna
A
Argnani
Rafaela
R
Caselli
Elisabetta
E
Zucchini
Silvia
S
Miriagou
Vivì
V
Mavromara
Penelope
P
Cilli
Michele
M
Grossi
Maria Pia
MP
Balboni
Pier Giorgio
PG
Cassai
Enzo
E
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000276:immunology* / Q000517:prevention & control; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*
D006023:Glycoproteins; D022301:Herpes Simplex Virus Vaccines; D022283:Herpesvirus Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C044525:glycoprotein B, herpes simplex virus type 2; C044768:glycoprotein E, herpes simplex virus type 1; C069093:herpes simplex virus-1 glycoprotein D vaccine